%PDF-1.6
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2013-07-15T17:12:52-03:00
2013-07-15T17:12:53-03:00
2013-07-15T17:12:53-03:00
Adobe InDesign CS6 (Macintosh)
uuid:fbf60d90-8b33-6a4d-a5ab-4c771b0f766c
xmp.did:28BE0F2E7982E1119CCD82983846A8CE
xmp.id:985793BB3C206811822A9D32B4FA6D5B
proof:pdf
xmp.iid:EC7AB77339206811822A9D32B4FA6D5B
xmp.did:EA7AB77339206811822A9D32B4FA6D5B
xmp.did:28BE0F2E7982E1119CCD82983846A8CE
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CS6 (Macintosh)
/
2013-07-15T17:12:52-03:00
application/pdf
Adobe PDF Library 10.0.1
False
endstream
endobj
5 0 obj
<>
endobj
3 0 obj
<>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 595.276 793.701]/Type/Page>>
endobj
8 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 595.276 793.701]/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 595.276 793.701]/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text/ImageB]/XObject<>>>/TrimBox[0.0 0.0 595.276 793.701]/Type/Page>>
endobj
11 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 595.276 793.701]/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 595.276 793.701]/Type/Page>>
endobj
40 0 obj
<>stream
q
/GS0 gs
/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/TT0 1 Tf
7 0 0 7 547.9252 31.0197 Tm
(179)Tj
ET
q
0 g
/GS0 gs
/Fm1 Do
Q
BT
/TT1 1 Tf
10.5 0 0 10.5 42.5197 701.3482 Tm
(References)Tj
/TT0 1 Tf
0.46 Tw 8 0 0 8 42.5197 677.0135 Tm
(1.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Druker BJ, Guilhot )0.6(F)79.5(, O\222Brien SG, Gathmann )0.6(I, Kantarjian )0.9(H, )]TJ
0.223 Tw 0 -1.25 TD
[(Gattermann )0.9(N, Deininger )0.5(MW)91.8(, Silver )0.5(R)59.6(T)73.9(, Goldman )0.5(JM, Stone RM, )]TJ
-0.048 Tw T*
[(Cervantes )0.9(F)79.4(, Hochhaus )54.9(A, Powell )0.5(BL, )0.6(Gabrilove )0.8(JL, Rousselot )0.6(P)110.7(, Reif)17.9(fers )]TJ
0.066 Tw T*
[(J, Cornelissen )0.5(JJ, Hughes )18(T)73.9(, )55.2(Agis H, Fischer )18.2(T)73.9(, )18.2(V)110.6(erhoef )0.8(G, Shepherd )0.7(J, )]TJ
0.091 Tw T*
[(Saglio G, Gratwohl )54.5(A, Nielsen JL, Radich JP)110.6(, Simonsson B, )17.3(T)70(aylor K, )]TJ
0.023 Tw T*
[(Baccarani )1.1(M, So C, Letvak )0.8(L, Larson RA; IRIS Investigators. )0.7(Five-year )]TJ
0.095 Tw T*
[(follow-up of patients )0.9(receiving )1.1(imatinib )1.3(for chronic )0.7(myeloid )0.9(leukemia. )]TJ
/C2_0 1 Tf
0 Tw T*
[<00310003>-208.6<00280051004A004F0003>-208.1<002D0003>-208.6<00300048004700110003>-208.5<0015001300130019001E001600180018000B00150016000C001D001500170013001B00100014001A00110003>-208.4<00260052005000500048005100570003>-207.8<004C0051001D0003>-208.1<00310003>-208.6<00280051004A004F0003>-208.1<002D0003>-208.6<00300048004700110003>]TJ
T*
<001500130013001A001E001600180019000B0014001A000C001D0014001A001B0013001E0003004400580057004B005200550003005500480053004F005C00030014001A001B00130011>Tj
/TT0 1 Tf
0.601 Tw -1.772 -1.604 Td
(2.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Cortes JE, Egorin MJ, )-0.7(Guilhot F)79.4(, Molimard M, Mahon FX. )]TJ
1.198 Tw T*
[(Pharmacokinetic/pharmacodynamic )3.1(correlation )1.2(and )0.6(blood-level )]TJ
0.209 Tw T*
[(testing in imatinib )0.7(therapy for chronic myeloid leukemia. )0.6(Leukemia. )]TJ
/C2_0 1 Tf
0 Tw T*
<001500130013001C001E00150016000B001C000C001D001400180016001A0010001700170011>Tj
/TT0 1 Tf
0.188 Tw -1.772 -1.604 Td
(3.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Agrawal M, Gar)17.5(g RJ, Cortes J, Quint\341s-Cardama )55.4(A. )17.4(T)69.9(yrosine kinase )]TJ
/C2_0 1 Tf
0 Tw T*
<004C0051004B004C0045004C0057005200550056001D00030057004B0048000300C000550056005700030047004800460044004700480011000300260058005500550003002B00480050004400570052004F000300300044004F004C004A0003003500480053001100030015001300140013001E0018000B0015000C001D001A00130010001B00130011>Tj
/TT0 1 Tf
0.06 Tw -1.772 -1.604 Td
(4.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Ibrahim )54.9(AR, Eli)0.5(asson L, )54.6(Apperley JF)79.5(, Milojkovic D, Bua M, Szydlo R, )]TJ
0.065 Tw T*
[(et )0.8(al. )0.7(Poor adherenc)0.6(e )0.6(is the )0.8(main )0.9(reason for loss of )0.5(CCyR and )0.6(imatinib )]TJ
0.263 Tw T*
[(failure )0.9(for chronic )0.8(myeloid )1(leukemia )1.2(patients )1(on long-term )1(therapy)65.4(. )]TJ
/C2_0 1 Tf
0 Tw T*
[<0025004F00520052004700110003001500130014>36.8<0014001E0014>36.8<0014001A000B00140017000C001D0016001A00160016001000190011>]TJ
/TT0 1 Tf
0.224 Tw -1.772 -1.604 Td
(5.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Onitilo )55.8(AA, Engel )0.7(JM. Managing )0.7(relapse )0.8(of CML)36.6( using therapeutic )]TJ
/C2_0 1 Tf
0 Tw T*
[<004C005000440057004C0051004C004500030053004F00440056005000440003004F004800590048004F001100030026004F004C00510003>57.1<0024004700590003002B00480050004400570052004F00030032005100460052004F00110003001500130013001C001E001A000B0014>37.4<0014000C001D001A001900160010001A0011>]TJ
/TT0 1 Tf
0.167 Tw -1.772 -1.604 Td
(6.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Larson RA, Druker BJ, Guilhot )0.8(F)79.4(, O\222Brien )0.7(SG, Riviere )1(GJ, Krahnke )]TJ
0.13 Tw T*
[(T)73.9(, Gathmann )0.6(I, )17.8(W)79.7(ang )37(Y)91.6(; IRIS International )1.3(Randomized )1(Interferon )0.6(vs )]TJ
0.287 Tw T*
[(STI571 )0.5(Study )0.6(Group. Imatinib )1.4(pharmacokinetics )1.8(and )0.7(its )0.7(correlation )]TJ
/C2_0 1 Tf
0 Tw T*
[<005A004C0057004B0003>-71.8<005500480056005300520051005600480003>-72<0044005100470003>-71.9<00560044004900480057005C0003>-71.6<004C00510003>-71.8<0046004B005500520051004C004600100053004B0044005600480003>-71.4<0046004B005500520051004C00460003>-71.5<0050005C0048004F0052004C00470003>-71.3<004F00480058004E00480050004C0044001D0003>-70.9<00440003>]TJ
T*
[<005600580045004400510044004F005C0056004C005600030052004900030057004B00480003002C0035002C003600030056005700580047005C>65.3<001100030025004F00520052004700110003001500130013001B001E0014>36.9<0014>36.7<0014000B001B000C001D00170013001500150010001B00110003>]TJ
/TT0 1 Tf
0.433 Tw -1.772 -1.604 Td
(7.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Faber )0.6(E, )0.5(Friedeck\375 )0.6(D, Micov\341 )0.6(K, Divok\341 )0.7(M, Katrincs\341kov\341 )0.9(B, )]TJ
-0.032 Tw T*
[(Rozmanov\341 )0.9(S, et )0.6(al. )0.6(Imatinib )1(dose escala)0.6(tion )0.6(in two patients )0.8(with chronic )]TJ
0.075 Tw T*
[(myeloid )0.9(leukemia, )0.9(with )0.6(low trough )0.5(imatinib )0.8(plasma )0.7(levels )0.7(measured )0.7(at )]TJ
0.195 Tw T*
(various intervals from the beginning of therapy and with suboptimal )Tj
-0.007 Tw T*
[(treatment )1.4(response, leads )0.6(to )0.5(the )0.6(achievement )1.6(of higher )0.7(plasma )0.8(levels )0.8(and )]TJ
/C2_0 1 Tf
0 Tw T*
<00500044004D00520055000300500052004F004800460058004F0044005500030055004800560053005200510056004800110003002C005100570003002D0003002B00480050004400570052004F001100030015001300140013001E001C0014000B0018000C001D001B001C001A0010001C001300150011>Tj
/TT0 1 Tf
-0.017 Tw -1.772 -1.604 Td
(8.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Singh )0.7(N, Kumar )0.5(L, )0.6(Meena )0.8(R, )18.1(V)110.7(elpandian )18.4(T)73.9(. )0.5(Drug monitoring )1.1(of )0.5(imatinib )]TJ
/C2_0 1 Tf
0 Tw T*
[<004F004800590048004F00560003>-183.3<004C00510003>-183.6<005300440057004C00480051005700560003>-183.1<00580051004700480055>17.7<004A0052004C0051004A0003>-183.6<0057004B0048005500440053005C0003>-183.3<0049005200550003>-183.8<0046004B005500520051004C00460003>-183.3<0050005C0048004F0052004C00470003>-183.1<004F00480058004E004400480050004C0044001D0003>]TJ
/TT0 1 Tf
0.087 Tw T*
[(comparing )0.5(plasma levels of responders and non-responders. Eur J Clin )]TJ
/C2_0 1 Tf
0 Tw T*
<0033004B004400550050004400460052004F00110003001500130013001C001E000300190018000B0019000C001D0018001700180010001C0011>Tj
-1.772 -1.604 Td
<001C0011>Tj
/Span<>> BDC
<0003>Tj
EMC
1.772 0 Td
[<0036004400450044005700480003>-434.6<002800110003>-380.3<00240047004B0048005500480051004600480003>-434.9<005700520003>-435<004F00520051004A001000570048005500500003>-434.6<0057004B0048005500440053004C00480056001D0003>-434.6<00480059004C004700480051004600480003>-434.4<0049005200550003>-435.3<004400460057004C005200510003>]TJ
T*
[<003E002C0051005700480055005100480057004000110003>-105.2<002A00480051004800590044001D0003>-87.7<003A>79.7<00520055004F00470003>-105.6<002B00480044004F0057004B0003>-105.2<00320055>17.4<004A00440051004C005D00440057004C00520051001E0003>-104.7<001500130013001600110003>-105.8<003E0046004C0057004800470003>-105.1<00150013001400150003>-105.8<0031005200590003>]TJ
T*
[<00150014004000110003>-326<0024>73.6<00590044004C004F00440045004F00480003>-380.1<0049005500520050001D0003>-380.5<004B005700570053001D00120012005A005A005A>65.3<0011005A004B00520011004C0051005700120046004B00530012004E00510052005A004F00480047004A00480012005300580045004F004C004600440057004C0052005100560012>]TJ
/TT0 1 Tf
T*
(adherence_introduction.pdf)Tj
/C2_0 1 Tf
-1.772 -1.604 Td
<001400130011>Tj
/Span<>> BDC
<0003>Tj
EMC
1.772 0 Td
[<002B0044004F0049004700440051004400550056005200510003>-360.4<00370035000F0003>-378.4<002D004400570052004C0003>-323.4<002400110003>-378.6<003200550044004F0003>-378.2<0046004400510046004800550003>-378.3<0046004B0048005000520057004B0048005500440053005C001D0003>-377.3<0057004B00480003>-378<00460055004C0057004C00460044004F0003>]TJ
/TT0 1 Tf
0.048 Tw T*
[(interplay between patient education and patient safety)65.3(. Curr Oncol Rep. )]TJ
/C2_0 1 Tf
0 Tw T*
<0015001300140013001E00140015000B0017000C001D00150017001A0010001800150011>Tj
/TT0 1 Tf
0.197 Tw -1.772 -1.604 Td
[(1)36.6(1.)]TJ
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Cramer JA, )-0.7(Roy )54.4(A, )-0.6(Burrell )54.9(A, Fairchild CJ, Fuldeore MJ, )-0.7(Ollendorf )]TJ
/C2_0 1 Tf
0 Tw T*
[<00270024000F0003>-251.4<004800570003>-250.7<0044004F00110003>-250.7<003000480047004C004600440057>0.6<004C005200510003>-250.8<0046005200500053004F004C00440051004600480003>-249.9<0044005100470003>-250.9<0053004800550056004C005600570048005100460048001D0003>-250.3<0057004800550050004C00510052004F0052004A005C0003>-250.2<0044005100470003>]TJ
T*
[<0047004800C00051004C0057004C00520051005600110003>-84.2<0039>110.7<0044004F005800480003>-101.7<002B00480044004F0057004B00110003>-101.6<001500130013001B001E0014>36.8<0014000B0014000C001D001700170010001A00110003>-102<00260052005000500048005100570003>-101.4<004C0051001D0003>-84.2<0039>110.7<0044004F005800480003>-101.7<002B00480044004F0057004B00110003>]TJ
T*
<001500130013001C001E00140015000B0017000C001D0019001600130011>Tj
/TT0 1 Tf
0.039 Tw -1.772 -1.604 Td
(12.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Peterson )55.2(AM, Nau DP)110.5(, Cramer )0.6(JA, Benner )0.5(J, Gwadry-Sridhar F)79.5(, Nichol )]TJ
0.05 Tw T*
[(M. )54.5(A)54.5( chec)0.5(klist for medication )1(compliance )1.1(and persistence )0.6(studies using )]TJ
/C2_0 1 Tf
0 Tw T*
[<0055004800570055005200560053004800460057004C00590048000300470044005700440045004400560048005600110003>19<0039>110.6<0044004F005800480003002B00480044004F0057004B00110003001500130013001A001E00140013000B0014000C001D00160010001400150011>]TJ
/TT0 1 Tf
0.163 Tw -1.772 -1.604 Td
(13.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Darkow )17.8(T)73.9(, Henk HJ, )17.5(Thomas )0.5(SK, Feng )18(W)91.9(, Baladi )0.9(JF)79.3(, Goldber)17.7(g GA, )]TJ
0.289 Tw 33.661 69.981 Td
[(et al. )18.1(T)34.8(reatment )1.1(interruptions )0.7(and non-adherence )0.8(with imatinib )1.1(and )]TJ
/C2_0 1 Tf
0 Tw T*
[<00440056005600520046004C00440057004800470003>-235<004B00480044004F0057004B00460044005500480003>-234.5<00460052005600570056001D0003>-235.5<00440003>-235.5<0055004800570055005200560053004800460057004C005900480003>-234.6<004400510044004F005C0056004C00560003>-235.3<0044005000520051004A0003>-235.3<0050004400510044004A004800470003>]TJ
/TT0 1 Tf
-0.035 Tw T*
[(care )0.9(patients )1(with )0.6(chronic )0.9(myelogenous )0.8(leukaemia. )1.6(Pharmacoeconomics. )]TJ
/C2_0 1 Tf
0 Tw T*
<001500130013001A001E00150018000B0019000C001D0017001B00140010001C00190011>Tj
/TT0 1 Tf
0.091 Tw -1.772 -1.604 Td
(14.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Eliasson L, Clif)17.9(ford S, Barber N, Marin D. Exploring chronic myeloid )]TJ
0.108 Tw T*
[(leukemia )0.6(patients\222)74.3( reasons for not adhering to the oral anticancer )0.7(drug )]TJ
/C2_0 1 Tf
0 Tw T*
[<004C005000440057004C0051004C00450003004400560003005300550048005600460055004C00450048004700110003002F00480058004E000300350048005600110003001500130014>38.4<0014001E00160018000B0018000C001D0019001500190010001600130011>]TJ
/TT0 1 Tf
0.101 Tw -1.772 -1.604 Td
(15.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Baccarani )0.8(M, Cortes J, Pane F)79.5(, Niederwieser D, Saglio G, )54.4(Apperley J, )]TJ
-0.048 Tw T*
[(Cervantes F)79.5(, Deininger M, Gratwohl )54.6(A, Guilhot F)79.4(, Hochhaus )54.4(A, Horowitz )]TJ
0.117 Tw T*
[(M, Hughes )17.4(T)73.9(, Kantarjian )0.6(H, Larson R, Radich J, Simonsson B, Silver )]TJ
0.021 Tw T*
[(R)59.6(T)73.9(, Goldman J, Hehlmann )0.6(R; European )0.6(LeukemiaNet)]TJ
/TT2 1 Tf
0 Tw 21.764 0 Td
(.)Tj
/TT0 1 Tf
0.021 Tw [( Chronic )0.5(myeloid )]TJ
/C2_0 1 Tf
0 Tw -21.764 -1.25 Td
[<004F00480058004E00480050004C0044001D0003>-83.5<004400510003>-84.4<0058005300470044005700480003>-84.1<005200490003>-84.6<004600520051004600480053005700560003>-84.1<0044005100470003>-84.5<0050004400510044004A004800500048005100570003>-83.6<00550048004600520050005000480051004700440057004C0052005100560003>-83.5<005200490003>]TJ
T*
[<002800580055005200530048004400510003>-79<002F00480058004E00480050004C0044>0.9<00310048005700110003>-79.3<002D0003>-79.7<0026004F004C00510003>-79.2<0032005100460052004F00110003>-79.3<001500130013001C001E0015001A000B00160018000C001D001900130017001400100018001400110003>-79.2<00260052005000500048005100570003>]TJ
T*
[<004C0051001D0003002D00030026004F004C005100030032005100460052004F001100030015001300140013001E0015001B000B0014001B000C001D0048001600140013001E0003004400580057004B005200550003005500480053004F005C0003004800160014>38.7<00140011>]TJ
/TT0 1 Tf
0.111 Tw -1.772 -1.604 Td
(16.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Marin D, Bazeos )54.3(A, Mahon FX, )-0.6(Eli)0.5(asson L, Milojkovic D, Bua M, et )]TJ
0.18 Tw T*
[(al. )54.8(Adherence is the critical )0.9(factor for achieving )0.6(molecular )0.7(responses )]TJ
0.376 Tw T*
[(in patients )0.7(with chronic myeloid )0.7(leukemia )1(who achieve )0.8(complete )]TJ
/C2_0 1 Tf
0 Tw T*
<0046005C00570052004A0048005100480057004C004600030055004800560053005200510056004800560003005200510003004C005000440057004C0051004C004500110003002D00030026004F004C005100030032005100460052004F001100030015001300140013001E0015001B000B00140017000C001D00150016001B00140010001B0011>Tj
/TT0 1 Tf
-0.02 Tc 0.057 Tw -1.772 -1.604 Td
(17.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Ganesan P)110.7(, Sagar )17.8(TG, Dubashi B, Rajendranath R, Kannan K, Cyriac S, et)-19.8( )]TJ
0.002 Tw T*
[(al. Nonadherence to imatinib adversely af)17.6(fects event free survival in chronic)-19.9( )]TJ
/C2_0 1 Tf
0.02 Tw T*
[<0053004B00440056004800030046004B005500520051004C004600030050005C0048004F0052004C00470003004F00480058004E00480050004C004400110003>54.7<002400500003002D0003002B00480050004400570052004F00110003001500130014>36.6<0014001E001B0019000B0019000C001D0017001A0014001000170011>]TJ
/TT0 1 Tf
0 Tc 0.144 Tw -1.772 -1.604 Td
(18.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(de Lavallade )0.8(H, )54.4(Apperley JF)79.3(, Khorashad JS, )-0.6(Milojkovic D, Reid )54.7(AG, )]TJ
-0.032 Tw T*
[(Bua M, et )0.6(al. )0.5(Imatinib )1.2(for newly )0.5(diagnosed )0.5(patients )1(with chronic )0.8(myeloid )]TJ
/C2_0 1 Tf
0 Tw T*
[<004F00480058004E00480050004C0044001D0003>-369<004C00510046004C00470048005100460048>0.9<0003>-370.2<005200490003>-370.2<00560058005600570044004C0051004800470003>-369.8<0055004800560053005200510056004800560003>-370.4<004C00510003>-370<004400510003>-370<004C00510057004800510057004C005200510010005700520010005700550048004400570003>]TJ
T*
[<004400510044004F005C0056004C005600110003>9.5<002D0003>9<0026004F004C00510003>9.5<0032005100460052004F00110003>9.4<001500130013001B001E00150019000B00150013000C001D001600160018001B00100019001600110003>9.4<00260052005000500048005100570003>9.9<004C0051001D0003>9.5<002D0003>9<0026004F004C00510003>9.5<0032005100460052004F00110003>]TJ
T*
<001500130013001B001E00150019000B00150013000C001D001600160013001B0010001C0011>Tj
/TT0 1 Tf
0.06 Tw -1.772 -1.604 Td
(19.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Noens L, van Lierde )0.6(MA, De Bock R, )17.5(V)110.7(erhoef G, Zach\351e )0.8(P)110.6(, Berneman )]TJ
0.196 Tw T*
[(Z, )0.6(et )0.7(al. )0.8(Prevalence, )1.4(determinants, )1.3(and outcomes )0.9(of nonadherence )1.2(to )]TJ
/C2_0 1 Tf
0 Tw T*
[<004C005000440057004C0051004C00450003>59<0057004B0048005500440053005C0003>58.5<004C00510003>58.1<005300440057004C00480051005700560003>58.7<005A004C0057004B0003>58.2<0046004B005500520051004C00460003>58.4<0050005C0048004F0052004C00470003>58.7<004F00480058004E00480050004C0044001D0003>59.1<0057004B00480003>113<002400270024002A002C00320003>]TJ
T*
[<0056005700580047005C>64.9<001100030025004F00520052004700110003001500130013001C001E0014>37<00140016000B00150015000C001D001800170013001400100014>36.8<001400110003>]TJ
/TT0 1 Tf
-0.024 Tw -1.772 -1.604 Td
(20.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Brasil. )0.7(Minist\351rio )0.5(da Sa\372de. )0.5(Secret\341)0.6(ria )0.7(de )55.1(Aten\347\343o )0.8(\340 )0.5(Sa\372de. Portaria )0.8(SAS )]TJ
0.089 Tw T*
[(n. 431, de 3 de outubro de 2001. Protocolo e Diretrizes )18.3(T)69.9(erap\352uticas )1(\226 )]TJ
0.012 Tw T*
[(Leucemia )1(Miel\363ide )0.5(Cr\364nica do )54.6(Adulto, bem como os modelos de )17.6(T)70(ermo )]TJ
/C2_0 1 Tf
0 Tw T*
[<004700480003>-127.8<0026005200510056004800510057004C005000480051005700520003>-127.2<002C005100490052005500500044004700520003>-127.7<00470048004F00480003>-127.5<004C005100570048004A0055004400510057004800560003>-127.2<003E002C0051005700480055005100480057004000110003>-127.4<00250055004400560074004F004C0044001D0003>-127.2<00300036001E0003>]TJ
T*
[<001500130013001400110003>37.8<003E0046004C0057004800470003>38.5<001500130014>36.6<00140003>37.8<0032004600570003>38<0016004000110003>92.5<0024>73.5<00590044004C004F00440045004F00480003>38.8<0049005500520050001D0003>38.1<004B005700570053001D0012001200470057005500150013001300140011005600440058004700480011004A00520059>66.1<00110045005500120056004400560012>]TJ
/TT0 1 Tf
T*
[(POR)59.3(T)79.7(ARIAS/Port2001/PT)91.7(-431.htm)]TJ
0.084 Tw -1.772 -1.604 Td
(21.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Brasil. Minist\351rio da Sa\372de. Secret)0.5(\341ria de )54.7(Aten\347\343o \340 Sa\372de. Portaria n. )]TJ
0.065 Tw T*
[(347, )0.5(de )0.6(23 )0.5(de )0.6(junho )0.5(de )0.6(2008. )55.2(Altera\347\343o)0.7( )0.5(do )0.5(anexo )0.8(da )0.6(portaria )1.1(SAS 432, )]TJ
-0.021 Tw T*
[(de 03 de outubro de 2001. Protocolo e Diretrizes )18(T)69.9(erap\352uticas- )0.7(Leucemia )]TJ
0.071 Tw T*
[(Miel\363ide Cr\364nica do )54.3(Adulto [Internet]. Bras\355lia; MS; )-0.6(2008. [cited 2012 )]TJ
/C2_0 1 Tf
0 Tw T*
[<002D005800510003>-618.7<00150014004000110003>-563.8<0024>73.5<00590044004C004F00440045004F00480003>-617.5<0049005500520050001D0003>-618.2<004B005700570053001D00120012004500590056005000560011005600440058004700480011004A00520059>65.8<0011004500550012004500590056001200560044005800470048004F0048004A004C00560012>]TJ
/TT0 1 Tf
T*
(sas/2008/prt0347_23_06_2008.html)Tj
-0.017 Tw -1.772 -1.604 Td
(22.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Deininger )0.6(MW)91.8(, O\222Brien SG, Ford JM, Druker JB. Practical )0.9(management )]TJ
0.192 Tw T*
[(of patients )0.6(with chronic )0.5(myeloid )0.7(leukemia )0.5(receiving )0.8(imatinib. )1(J Clin )]TJ
/C2_0 1 Tf
0 Tw T*
<0032005100460052004F001100030015001300130016001E00150014000B001B000C001D001400190016001A00100017001A0011>Tj
/TT0 1 Tf
0.047 Tw -1.772 -1.604 Td
(23.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Brasil. )0.7(Minist\351rio )0.5(da )0.6(Sa\372de. )0.6(Portaria )0.9(SAS/MS n. )0.5(90, de )0.5(15 )0.5(de )0.5(mar\347o )0.9(de )]TJ
0.07 Tw T*
[(201)36.6(1. Estabelece )0.7(o Protocolo cl\355nico e diretrizes )17.9(T)70(erap\352uticas )0.5(do tumor )]TJ
/C2_0 1 Tf
0 Tw T*
[<004700520003>-33.1<00480056005700550052005000440003>-32.7<004A00440056005700550052004C00510057004800560057004C00510044004F0003>-32<000B002A002C00360037000C0003>-33.3<003E002C0051005700480055005100480057004000110003>-32.5<00250055004400560074004F004C0044001D0003>-32.4<00300036001E0003>-33.2<001500130014>36.6<001400110003>-33.1<003E0046004C0057004800470003>]TJ
T*
[<00150013001400150003>-122.8<002D005800510003>-123<00150014004000110003>-68.2<0024>73.6<00590044004C004F>0.5<00440045004F00480003>-122.4<0049005500520050001D0003>-122.5<004B005700570053001D00120012005A005A005A>65.2<00110045005500440056004C004F00560058005600110046005200500011004500550012004F0048004A004C0056004F004400460052004800560012>]TJ
/TT0 1 Tf
T*
(sas/107525-90.html)Tj
-0.005 Tw -1.772 -1.604 Td
(24.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Nonino )55.2(A. Problemas )0.8(e )0.5(perspectivas)0.6( do tratamento )1.5(da leucemia )1.5(mieloide )]TJ
/C2_0 1 Tf
0 Tw T*
[<0046005500520051004C0046004400030051005200030025005500440056004C004F00110003003500480059000300250055004400560003002B00480050004400570052004F0003002B004800500052005700480055>56.9<00110003001500130013001B001D00160013000B003600580053004F0014000C001900190010001C0011>]TJ
/TT0 1 Tf
0.037 Tw -1.772 -1.604 Td
(25.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Ruddy K, Mayer E, Partridge )55.3(A. Patient )0.7(adherence )0.9(and persistence )0.8(with )]TJ
/C2_0 1 Tf
0 Tw T*
[<005200550044004F0003004400510057004C00460044005100460048005500030057005500480044005700500048005100570011000300260024>57.1<00030026004400510046004800550003002D00030026004F004C005100110003001500130013001C001E0018001C000B0014000C001D001800190010001900190011>]TJ
ET
0.2 1 0.7 0.2 K
0.5 w 4 M
/GS0 gs
q 1 0 0 1 123.1299 110.5332 cm
0 0 m
164.409 0 l
S
Q
BT
/GS1 gs
/TT0 1 Tf
9.5 0 0 9.5 293.1703 108.4707 Tm
(xxx)Tj
ET
/GS0 gs
q 1 0 0 1 313.0512 110.5332 cm
0 0 m
164.409 0 l
S
Q
endstream
endobj
32 0 obj
<>>>/Subtype/Form>>stream
0.2 1 0.7 0.2 K
0.5 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 42.5197 746.1004 cm
0 0 m
515.906 0 l
S
Q
endstream
endobj
33 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
BT
0 0 0 1 k
/GS0 gs
/C2_0 1 Tf
-0.01 Tc 0.01 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 93.418 749.3937 Tm
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
/TT0 1 Tf
0 Tc 0 Tw 7 0 0 7 42.5197 31.0197 Tm
[(Rev Bras Hematol Hemoter)56(. 2013;35\(3\):174-79)]TJ
ET
endstream
endobj
41 0 obj
<>
endobj
42 0 obj
<>
endobj
45 0 obj
<>
endobj
46 0 obj
<>stream
H\n0EY&H)!Ģ5{HA,z(?:V xwMkñ;p[kEi-_Ճ2vmz|qr3ZoΠk
V_e
>?ء Ru,Mez;92،
C"S@~O!КbٵߵyLyNX6#9&N9%Θ3bŬ9oBy=|r9%g4/ُ$?sI%K撘%\싖+(b+ȿr)Tn+K}wηq:Ks^+ B
endstream
endobj
47 0 obj
<>stream
HytEƿU ;!lJu"FUe <
茣H%adHX>,!#y.{0!oTݪ{5@ULCQѣx p1ܗF͋ ;~KoT~ccEF9;
h?NRN5U9uU=PgWGG`VbG_ώ[!_7j\Lɭ<гOkїR' V3Ub*
7.Tyg>}b5
e+ e5oWih4"v.TD,Da1,2,GV+|HDVa
z|
؈M،[
HvTcb/U?qIi#Ȃgx`,~9C>. WP"*Jp
6$PB(jP05$BG5RuԉPwIOP8=I/=K@LhE[KDD,(()r"S!jjN
цjҴZ]bʂX0YbmX[֑gX{&lfl&bY[ΒV
'q9+ʼ
ʫ<~Yޟ?|̇y>\>/|_
|S ~Y#?ϋ5+"T,Alb-RqHߋS"G(W5A_Їkw=YߡGz~A_BnQͨm7
aF2F' c*T
iHHI.
rjk+y]KDZp_W,;㣷qv_s/u?Ǡ@HUqMdSKjpܖ+è3uḷԟ Bi$ROwoqxmWgYeq&~791ǁǵXq#֔dox=8Jq-'Os><|8'yOxx2 Vb,RGaqLi#ΊQ,JttCs